menu
    • menu
    [{"orgOrder":0,"company":"NexThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"KOSOVO","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"NT-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"NexThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NexThera \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NexThera \/ Inapplicable"},{"orgOrder":0,"company":"NexThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"KOSOVO","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"NT-101","moa":"PEDF","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"NexThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"NexThera \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NexThera \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by NexThera

    Menu

    NexThera

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NexThera

                            Kosovo arrow
                            AACR Annual meeting
                            Not Confirmed

                            NexThera

                            Kosovo arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NT-101

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NexThera Enrolls First Patient in U.S. Trial for NT-101 Wet AMD Drop

                            Details : NT-101 is a PDEF modulator peptide drug candidate, which is currently being evaluated for the treatment of patients with wet age-related macular degeneration.

                            Product Name : NT-101

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            April 09, 2025

                            Lead Product(s) : NT-101

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NexThera

                            Kosovo arrow
                            AACR Annual meeting
                            Not Confirmed

                            NexThera

                            Kosovo arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NT-101

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NexThera Files IND for Phase 1/2a Trial of NT-101 Eye Drop for Wet AMD

                            Details : NT-101 is a PDEF modulator peptide drug candidate, which is currently being evaluated for the treatment of patients with wet age-related macular degeneration.

                            Product Name : NT-101

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            July 16, 2024

                            Lead Product(s) : NT-101

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth